Fatty acid synthase inhibition activates AMP-activated protein kinase in SKOV3 human ovarian cancer cells

Cancer Research

Volumn 67, Issue 7, 2007, Pages 2964-2971

  Zhou, Weibo ^a   Wan, Fang Han ^a   Landree, Leslie E ^a   Thupari, Jagan N ^a   Pinn, Michael L ^a   Bililign, Tsion ^b   Eun, Kyoung Kim ^a   Vadlamudi, Aravinda ^c   Medghalchi, Susan M ^c   El Meskini, Rajaa ^c   Ronnett, Gabriele V ^a   Townsend, Craig A ^b   Kuhajda, Francis P ^a,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c FASgen Inc   (United States)

^d JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 TETRADECYLOXY 2 FUROIC ACID; ACETYL COENZYME A CARBOXYLASE; ADENOSINE; ADENOSINE PHOSPHATE; C 93; ENZYME INHIBITOR; FATTY ACID SYNTHASE; FATTY ACID SYNTHASE INHIBITOR; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG; 5 (TETRADECYLOXY) 2 FURANCARBOXYLIC ACID; 5-(TETRADECYLOXY)-2-FURANCARBOXYLIC ACID; FATTY ACID; FURAN DERIVATIVE; MULTIENZYME COMPLEX; NICOTINAMIDE ADENINE DINUCLEOTIDE; PROTEIN SERINE THREONINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG INHIBITION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FATTY ACID SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CANCER; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; TUMOR XENOGRAFT; WEIGHT REDUCTION; AMINO ACID SEQUENCE; ANIMAL; BAGG ALBINO MOUSE; DRUG ANTAGONISM; DRUG SCREENING; ENZYMOLOGY; METABOLISM; MOLECULAR GENETICS; OVARY TUMOR; OXIDATION REDUCTION REACTION; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; ENZYME ACTIVATION; ENZYME INHIBITORS; FATTY ACID SYNTHETASE COMPLEX; FATTY ACIDS; FEMALE; FURANS; GLUCOSE; HUMANS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; MULTIENZYME COMPLEXES; NAD; OVARIAN NEOPLASMS; OXIDATION-REDUCTION; PROTEIN-SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34248211595     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3439     Document Type: Article

References (69)

1. Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 2002;7 Suppl 5:20-8.
2. Bhoola S, Hoskins WJ. Diagnosis and management of epithelial ovarian cancer. Obstet Gynecol 2006;107:1399-410.
3. Wakil S. Fatty acid synthase, a proficient multifunctional enzyme. Biochemistry 1989;28:4523-30.
4. Alo PL, Visca P, Framarino ML, et al. Immunohistochemical study of fatty acid synthase in ovarian neoplasms. Oncol Rep 2000;7:1383-8.
5. Gansler TS, Hardman W III, Hunt DA, Schaffel S, Hennigar RA. Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum Pathol 1997;28:686-92.
6. Kuhajda FP. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 2006;66:5977-80.
7. Yang YA, Han WF, Morin PJ, Chrest FJ, Pizer ES. Activation of fatty acid synthesis during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Exp Cell Res 2002;279:80-90.
8. Yang YA, Morin PJ, Han WF, et al. Regulation of fatty acid synthase expression in breast cancer by sterol regulatory element binding protein-1c. Exp Cell Res 2003;282:132-7.
9. Van de Sande T, De Schrijver E, Heyns W, Verhoeven G, Swinnen JV. Role of the phosphatidylinositol 3′-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells. Cancer Res 2002;62:642-6.
10. Bull JH, Ellison G, Patel A, et al. Identification of potential diagnostic markers of prostate cancer and prostatic intraepithelial neoplasia using cDNA microarray. Br J Cancer 2001;84:1512-9.
11. Swinnen JV, Roskams T, Joniau S, et al. Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer 2002;98:19-22.
12. Epstein JI, Carmichael M, Partin AW. OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate. Urology 1995;45:81-6.
13. Pizer ES, Pflug BR, Bova GS, Han WF, Udan MS, Nelson JB. Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression. Prostate 2001;47:102-10.
14. Alo PL, Visca P, Marci A, Mangoni A, Botti C, Di Tondo U. Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer 1996;77:474-82.
15. Milgraum LZ, Witters LA, Pasternack GR, Kuhajda FP. Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma Clin Cancer Res 1997;3:2115-20.
16. Wang Y, Kuhajda FP, Sokoll LJ, Chan DW. Two-site ELISA for the quantitative determination of fatty acid synthase. Clin Chim Acta 2001;304:107-15.
17. Wang YY, Kuhajda FP, Cheng P, et al. A new model ELISA, based on two monoclonal antibodies, for quantification of fatty acid synthase. J Immunoassay Immunochem 2002;23:279-92.
18. Pizer E, Thupari J, Han W, et al. Malonyl-Coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res 2000;60:213-8.
19. Gabrielson EW, Pinn ML, Testa JR. Kuhajda FP. Increased fatty acid synthase is a therapeutic target in mesothelioma. Clin Cancer Res 2001;7:153-7.
20. Wang HQ, Altomare DA, Skele KL, et al. Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene 2005;24:3574-82.
21. De Schrijver E, Brusselmans K, Heyns W, Verhoeven G, Swinnen JV. RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res 2003;63:3799-804.
22. Pizer E, Wood F, Heine H, Romantsey F, Pasternack G, Kuhajda F. Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Cancer Res 1996;56:1189-93.
23. Kuhajda FP, Jenner K, Wood FD, et al. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci U S A 1994;91:6379-83.
24. Zhou W, Simpson PJ, McFadden JM, et al. Fatty acid synthase inhibition triggers apoptosis during S-phase in human cancer cells. Cancer Res 2003;63:7330-7.
25. Li JN, Gorospe M, Chrest FJ, et al. Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53. Cancer Res 2001;61:1493-9.
26. Menendez JA, Lupu R. RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells. Int J Mol Med 2005;15:33-40.
27. Menendez JA, Vellon L, Mehmi I, et al. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci U S A 2004;101:10715-20.
28. Kumar-Sinha C, Ignatoski KW, Lippman ME, Ethier SP, Chinnaiyan AM. Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer Res 2003;63:132-9.
29. Alli PM, Pinn ML, Jaffee EM, McFadden JM, Kuhajda FP. Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice. Oncogene 2005;24:39-46.
30. Kuhajda FP, Pizer EP, Li JL, Mani NS, Frehywot GL, Townsend CA Synthesis and anti-tumor activity of a novel inhibitor of fatty acid synthase. Proc Natl Acad Sci U S A 2000;97:3450-4.
31. Loftus TM, Jaworsky DE, Frehywot GL, et al. Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science 2000;288:2379-81.
32. Thupari JN, Kim EK, Moran TH, Ronnett GV Kuhajda FP. Chronic C75 treatment of diet-induced obese mice increases fat oxidation and reduces food intake to reduce adipose mass. Am J Physiol Endocrinol Metab 2004;287:E97-104.
33. Thupari JN, Landree LE, Ronnett GV, Kuhajda FP. C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity. Proc Natl Acad Sci U S A 2002;99:9488-502.
34. Nicot C, Napal L, Relat J, et al. C75 activates malonyl-CoA sensitive and insensitive components of the CPT system. Biochem Biophys Res Commun 2004;325:660-4.
35. Yang N, Kays JS, Skillman TR, Burns L, Seng TW, Hammond C. C75 activates carnitine palmitoyltransferase-1 in isolated mitochondria and intact cells without displacement of bound malonyl CoA. J Pharmacol Exp Ther 2005;312:127-33.
36. Landree LE, Hanlon AL, Strong DW, et al. C75, a fatty acid synthase inhibitor, modulates AMP-activated protein kinase to alter neuronal energy metabolism. J Biol Chem 2004;279:3817-27.
37. Kim EK, Miller I, Aja S, et al. C75, a fatty acid synthase inhibitor, reduces food intake via hypothalamic AMP-activated protein kinase. J Biol Chem 2004;279:19970-6.
38. Hardie DG, Carling D, Carlson M. The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell? Annu Rev Biochem 1998;67:821-55.
39. Kemp BE, Mitchelhill KI, Stapleton D, Michell BJ, Chen ZP, Witters LA, Dealing with energy demand: the AMP-activated protein kinase. Trends Biochem Sci 1999;24:22-5.
40. McFadden JM, Medghalchi SM, Thupari JN, et al. Application of a flexible synthesis of (5R)-thiolactomycin to develop new inhibitors of type I fatty acid synthase. J Med Chem 2005;48:946-61.
41. Woods A, Cheung PC, Smith FC, et al. Characterization of AMP-activated protein kinase β and γ subunits. Assembly of the heterotrimeric complex in vitro. J Biol Chem 1996;271:10282-90.
42. Xing Y, Musi N, Fujii N, et al. Glucose metabolism and energy homeostasis in mouse hearts overexpressing dominant negative a2 subunit of AMP-activated protein kinase. J Biol Chem 2003;278:28372-7.
43. Smith S, Abraham S. Fatty acid synthase from lactating rat mammary gland. Methods Enzymol 1975;35:65-74.
44. Aprahamian SA, Arslanian MJ, Wakil SJ. Comparative studies on the kinetic parameters and product analyses of chicken and rat liver and yeast fatty acid synthetase. Comp Biochem Physiol B Biochem Mol Biol 1982;71:577-82.
45. Jayakumar A, Tai MH, Huang WY, et al. Human fatty acid synthase: properties and molecular cloning Proc Natl Acad Sci U S A 1995;92:8695-9.
46. Watkins PA, Ferrell EV, Jr., Pedersen JI, Hoefler G. Peroxisomal fatty acid β-oxidation in HepG2 cells. Arch Biochem Biophys 1991;289:329-36.
47. Rubi B, Antinozzi PA, Herrero L, et al. Adenovirus-mediated overexpression of liver carnitine palmitoyltransferase I in INS1E cells: effects on cell metabolism and insulin secretion. Biochem J 2002;364:219-26.
48. Stocchi V, Cucchiarini L, Magnani M, Chiarantini L, Palma P, Crescentini G. Simultaneous extraction and reverse-phase high-performance liquid chromatographic determination of adenine and pyridine nucleotides in human red blood cells. Anal Biochem 1985;146:118-24.
49. Witters LA, Kemp BE. Insulin activation of acetyl-CoA carboxylase accompanied by inhibition of the 5′-AMP-activated protein kinase. J Biol Chem 1992;267:2864-7.
50. McFadden JM, Frehywot GL, Townsend CA. A flexible route to (5R)-thiolactomycin, a naturally occurring inhibitor of fatty acid synthesis. Org Lett 2002;4:3859-62.
51. Halvorson DL, McCune SA. Inhibition of fatty acid synthesis in isolated adipocytes by 5-(tetradecyloxy)-2-furoic acid. Lipids 1984;19:851-6.
52. Hardie DG, Hawley SA. AMP-activated protein kinase: the energy charge hypothesis revisited. BioEssays 2001;23:1112-9.
53. Woods A, Azzout-Marniche D, Foretz M, et al. Characterization of the role of AMP-activated protein kinase in the regulation of glucose-activated gene expression using constitutively active and dominant negative forms of the kinase. Mol Cell Biol 2000;20:6704-11.
54. Al-Khalili L, Chibalin AV, Yu M, et al. MEF2 activation in differentiated primary human skeletal muscle cultures requires coordinated involvement of parallel pathways. Am J Physiol Cell Physiol 2004;286:C1410-6.
55. Rattan R, Giri S, Singh AK, Singh I. 5-Aminoimidazole-4-carboxamide-l- β-4-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase (AMPK). J Biol Chem 2005;280:39582-93.
56. Pizer E, Pflug B, Bova G, Han W, Udan M, Nelson J. Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression. Prostate 2001;47:102-10.
57. Aja S, McFadden JM, Aplasca A, et al. Intracerebroventricular administration of either C89b, a stimulator of carnitinepalmitoyl-transferase-1 (CPT-1s), or cerulenin, an inhibitor of fatty acid synthase (FASi), reduces food intake and body weight in mice. Appetite 2006;46:339.
58. Hardie DG, Carting D. The AMP-activated protein kinase-fuel gauge of the mammalian cell? Eur J Biochem 1997;246:259-73.
59. Abbud W, Habinowski S, Zhang JZ, et al. Stimulation of AMP-activated protein kinase (AMPK) is associated with enhancement of Glut1-mediated glucose transport Arch Biochem Biophys 2000;380:347-52.
60. Kurth-Kraczek EJ, Hirshman MF, Goodyear LJ, Winder WW. 5′ AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle. Diabetes 1999;48:1667-71.
61. Marsin AS, Bertrand L, Rider MH, et al. Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Curr Biol 2000;10:1247-55.
62. Winder WW, Hardie DG. Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise. Am J Physiol 1996;270:E299-304.
63. Motoshima H, Goldstein BJ, Igata M, Araki E. AMPK and cell proliferation-AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol 2006;574:63-71.
64. Xiang X, Saha AK, Wen R, Ruderman NB, Luo Z. AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun 2004;321:161-7.
65. Imamura K, Ogura T, Kishimoto A, Kaminishi M, Esumi H. Cell cycle regulation via p53 phosphorylation by a 5′-AMP activated protein kinase activator, 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside, in a human hepatocellular carcinoma cell line. Biochem Biophys Res Commun 2001;287:562-7.
66. Igata M, Motoshima H, Tsuruzoe K, et al. Adenosine monophosphate- activated protein kinase suppresses vascular smooth muscle cell proliferation through the inhibition of cell cycle progression. Circ Res 2005;97:837-44.
67. Ruderman NB, Saha AK, Kraegen EW. Minireview: malonyl CoA, AMP-activated protein kinase, and adiposity. Endocrinology 2003;144:5166-71.
68. Funabashi H, Kawaguchi A, Tomoda H, Omura S, Okuda S, Iwasaki S, Binding site of cerulenin in fatty acid synthetase. J Biochem (Tokyo) 1989;105:751-5.
69. Weiss L, Hoffmann GE, Schreiber R, et al. Fatty-acid biosynthesis in man, a pathway of minor importance. Purification, optimal assay conditions, and organ distribution of fatty-acid synthase. Biol Chem Hoppe Seyler 1986;367:905-12.